drugset / Trial / NCT07363577
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.
Timeline
- Start
- 2026-03-25
- Primary completion
- 2027-06
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LB-102 | Small molecule | 50 mg | Oral |
| Subject | LB-102 | Small molecule | 100 mg | Oral |